Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo

Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline

Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix

Topline data from ORCA-1 trial expected in the Second Quarter of 2019

Topline data from ORCA-1 trial expected in the Second Quarter of 2019

Topline data from ORCA-1 trial expected in mid-2019

Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy

Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com

Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study